TY - JOUR
T1 - Neuropsychological care and rehabilitation of cancer patients with chemobrain
T2 - Strategies for evaluation and intervention development
AU - Jean-Pierre, Pascal
AU - Johnson-Greene, Douglas
AU - Burish, Thomas G.
N1 - Funding Information:
Acknowledgements Dr. Pascal Jean-Pierre acknowledges the support of the Walther Cancer Foundation, the Indiana University Clinical and Translational Science Institute (IU-CTSI), and the Harper Cancer Research Institute. This study was made possible in part by the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award Grant Number TR000163 (A. Shekhar, PI).
PY - 2014/8
Y1 - 2014/8
N2 - Malignant tumors and their various treatments such as chemotherapy, radiotherapy and hormonal therapy can deleteriously affect a large number of cancer patients and survivors on multiple dimensions of psychosocial and neurocognitive functioning. Oncology researchers and clinicians are increasingly cognizant of the negative effects of cancer and its treatments on the brain and its mental processes and cognitive outcomes. Nevertheless, effective interventions to treat cancer and treatment-related neurocognitive dysfunction (CRND), also known as chemobrain, are still lacking. The paucity of data on effective treatments for CRND is due, at least partly, to difficulties understanding its etiology, and a lack of reliable methods for assessing its presence and severity. This paper provides an overview of the incidence, etiology, and magnitude of CRND, and discusses the plausible contributions of psychological, motor function, and linguistic and behavioral complications to CRND. Strategies for reliable neuropsychological screening and assessment, and development and testing of effective ways to mitigate CRND are also discussed.
AB - Malignant tumors and their various treatments such as chemotherapy, radiotherapy and hormonal therapy can deleteriously affect a large number of cancer patients and survivors on multiple dimensions of psychosocial and neurocognitive functioning. Oncology researchers and clinicians are increasingly cognizant of the negative effects of cancer and its treatments on the brain and its mental processes and cognitive outcomes. Nevertheless, effective interventions to treat cancer and treatment-related neurocognitive dysfunction (CRND), also known as chemobrain, are still lacking. The paucity of data on effective treatments for CRND is due, at least partly, to difficulties understanding its etiology, and a lack of reliable methods for assessing its presence and severity. This paper provides an overview of the incidence, etiology, and magnitude of CRND, and discusses the plausible contributions of psychological, motor function, and linguistic and behavioral complications to CRND. Strategies for reliable neuropsychological screening and assessment, and development and testing of effective ways to mitigate CRND are also discussed.
KW - Cancer and cognition
KW - Cancer and memory problems
KW - Cancer and treatment-related neurocognitive dysfunction
KW - Chemobrain
KW - Chemotherapy
KW - Cognitive disorders
KW - Cognitive functioning
KW - Malignant tumors
KW - Mental performance
KW - Neoplasms
KW - Neuropsychological tests
UR - http://www.scopus.com/inward/record.url?scp=84905095032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905095032&partnerID=8YFLogxK
U2 - 10.1007/s00520-014-2162-y
DO - 10.1007/s00520-014-2162-y
M3 - Article
C2 - 24671433
AN - SCOPUS:84905095032
VL - 22
SP - 2251
EP - 2260
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 8
ER -
